Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DRUG CLINICAL SUPPLY AGREEMENTDrug Clinical Supply Agreement • January 13th, 2015 • Bellerophon Therapeutics LLC • Pharmaceutical preparations • New Jersey
This Drug Clinical Supply Agreement (this “Agreement”) is entered into as of February 9, 2014 (the “Effective Date”) by and between by and between INO Therapeutics LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (“Ikaria”), and Bellerophon Pulse Technologies LLC, a Delaware limited liability company, with offices at Perryville III Corporate Park, 53 Frontage Road, Third Floor, Hampton, NJ 08827 d/b/a Ikaria (“Pulse Technologies”). Ikaria and Pulse Technologies may be individually referred to as a “Party” and together as the “Parties.”
THIRD AMENDMENT TO DRUG CLINICAL SUPPLY AGREEMENTDrug Clinical Supply Agreement • April 26th, 2018 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT (this “Amendment”), effective as of the last date of signature hereof (the “Amendment Effective Date”), is made to that certain Drug Clinical Supply Agreement, dated as of February 9, 2014, by and between Bellerophon Pulse Technologies LLC (“Pulse Technologies”) and Mallinckrodt Manufacturing LLC, assignee of INO Therapeutics LLC (“Mallinckrodt”), as amended by Section 6 of that certain Second Amendment to Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement, dated as of July 27, 2015, and as amended further by that certain Second Amendment to Drug Clinical Supply Agreement and Third Amendment to Exclusive Cross-License, Technology Transfer and Regulatory Matters Agreement, dated as of November 16, 2015 (collectively, the “Agreement”). Capitalized terms used herein not otherwise defined shall have the meanings ascribed to them in the Agreement.
